Fighting MDR G-Negative Infections

Slides:

Advertisements

Similar presentations

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.

Advertisements

Enoch Omonge University of Nairobi

Management of Neutropenic Fevers in cancer patients Jerry Yu.

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.

Approach To Pneumonia. Pneumonia Importance Mechanism Classification & its benefit Diagnosis Treatment.

Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.

Carbapenemase- Producing Carbapenem-Resistant Enterobacteriaceae Nicole Hearon, HAI Epidemiologist Surveillance and Investigation Division Indiana State.

Infezioni invasive da Enterobacteriaceae Carbapenemico-Resistenti (CRE): da colonizzato a sepsi, quali fattori di rischio ? Roberto Luzzati Malattie Infettive,

Antimicrobial resistance surveillance in Ireland Results of invasive Klebsiella pneumoniae infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010.

Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,

1 Infectious Diseases in the Nursing Home Setting: Challenges and Opportunities for Clinical Investigation 감염내과 R2 김대호 / Prof. 이미숙 Manisha Juthani-Mehta.

Changing Epidemiology of Adult Bacterial Meningitis in Southern Taiwan: A Hospital-Based Study Infection 2008; 36: 15–22 W.-N. Chang, C.-H. Lu, C.-R. Huang,

Outcomes of Carbapenem-Resistant K. pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies Gopi Patel, MD; Shirish Huprikar, MD;

HAP and VAP Guidelines Update

Figure 1. Rate of antimicrobial resistance in S. pneumoniae

Upfront Combination Therapy vs Step-Up Approach for PAH:

Use of antibiotics.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Background Goals Methods Conclusions Results

Professor Alan Johnson Department of HCAI & AMR

Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London

Wasl Mohammed Al-Adsani, DO, PhD, FACP

Matteo Bassetti, MD, PhD Infectious Diseases Division

RISK RECOGNITION IN HEALTHCARE SETTINGS

Using the Toolkit to build a CPE policy

Starting Strong: Initial Evaluation of the Patient With HCV

Acute Heart Failure.

A Paradigm Shift in PAH.

The Clinical Enigma of Cardiogenic Shock

L. S. Tzouvelekis, A. Markogiannakis, E. Piperaki, M. Souli, G. L

The challenges of multi-drug-resistance in hepatology

Treatment of Complicated Intra-abdominal Infections

Statin Selection in Special Patient Populations: A Case Challenge

When Would You Use Single Inhaler Triple Therapy in COPD?

Combination Inhaled Therapy in COPD: The Impact of Recent Data

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

CPE: coming to a hospital near you!

GLOBAL POINT PREVALENCE SURVEY OF ANTIMICROBIAL CONSUMPTION AND RESISTANCE (GLOBAL-PPS): RESULTS OF ANTIMICROBIAL PRESCRIBING IN INDIA Dr. Sanjeev K Singh.

Inside COMBACTE network: global information for a global problem.

Statins and HIV:.

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.

When Is Intrathecal Drug Delivery Appropriate?

Meropenem-vaborbactam: A New Hope

Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit C. Verwaest Clinical Microbiology.

G. Höffken Clinical Microbiology and Infection

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

TRAINING PRESENTATION

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Combating the spread of carbapenemases in Enterobacteriaceae: a battle that infection prevention should not lose P. Savard, T.M. Perl Clinical Microbiology.

W. -L. Yu, M. -F. Lee, H. -J. Tang, M. -C. Chang, J

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Live on PAH: Breathing Life Into Patients With PAH

Clinical Challenges and Updates in Managing Seizure Clusters

Community-acquired pneumonia in adults

Evolving problems with resistant pathogens

When Is Intrathecal Drug Delivery Appropriate?

HF-Related Hospitalization and Readmissions

Incorporating New PAH Treatments Into Clinical Practice

E. Tacconelli Clinical Microbiology and Infection

Evaluating the Science of Cardiogenic Shock

MS, Age, and Immune Function

Pulmonary Arterial Hypertension and Hospitalizations

Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London

What's New in PAH?.

Presentation transcript:

Fighting MDR G-Negative Infections

What Is So Special About MDR GNB?

Resistance of CRE to Carbapenems

Classification and Characteristics of Major Carbapenemases in Enterobacteriaceae

Prevalence of Invasive CRE Infections Among Adult Patients in US Hospitals

Carbapenemase-Producing Enterobacteriaceae in the United States

Rise and Fall of KPC-Producing K Pneumoniae in New York City

Invasive K Pneumoniae Isolates With Resistance to Carbapenems, 2016

Prevalence of Carbapenem-Resistant K Pneumoniae in Different Provinces in China

Increasing Resistance of CRE K Pneumoniae in China

Reasons for the Increasing Prevalence of CRKP in China

CRE: Importance of Early and Effective Antibiotic Therapy

CRE Treatment and Assessment of Risk

Empiric Selection of Antibiotic Therapy

Selection of Empiric Therapy For Hospital-Acquired Infections

Importance of Local Epidemiology

Empirical Antibiotic Treatment Algorithm for HAP/VAP

Prediction Scores Studies for Certain ESKAPE Pathogens

CRE Infection: Combination Therapeutic Strategies

Treatment of CRE Infection in China: Challenges

KPC-2: Predominant Carbapenemase for CRKP in China

Treatment of CRE Infections in China

Ceftazidime-Avibactam: Clinical Considerations in Serious G-Negative Infections

Ceftazidime-Avibactam Treatment: Impact on Mortality

Meropenem-Vaborbactam: Clinical Considerations in Serious G-Negative Infections

TANGO II: Meropenem-Vaborbactam vs BAT in Patients With CR-Enterobacteriaceae Infections

Plazomicin: Clinical Considerations in Serious G-negative Infections

Plazomicin for Infections Caused by CRE: Results of the CARE Study

Eravacycline: Clinical Considerations in Serious G-Negative Infections

IGNITE 3: Eravacycline vs Ertapenem In cUTI

New Antibiotics in Development for the Treatment of CRE Infection

Features of a Successful Antibiotic Stewardship Program to Impact CRE

Program Summary

Abbreviations

Abbreviations (cont)